INCY vs RARE
Incyte vs Ultragenyx Pharmaceutical Inc. — AI-powered side-by-side comparison
VS
RARE
Ultragenyx Pharmaceutical Inc.
56
Watch
| Metric | INCY | RARE |
|---|
| AI Score |
72
|
56
|
| Price |
$121.08
|
$26.96
|
| P/E Ratio |
14.89×
|
-4.62×
|
| ROE |
24.9%
|
718.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
92.6%
|
83.1%
|
| Debt / Equity |
0.01×
|
-4.13×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
56.2
|
54.3
|
| Beta |
0.769
|
0.313
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for INCY versus RARE.
INCY leads by 16 points.
INCY scores 72/100 (Buy) versus RARE at 56/100 (Watch).
INCY Committee View
100% agreement
6 analysts
The primary driver is revenue growing 26.9% yoy -- genuine top-line momentum. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 29.6% shows genuine earnings power backing the valuation — Value
- Revenue growing 26.9% YoY -- genuine top-line momentum — Growth
- EPS growing 80.3% YoY — Growth
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
RARE Committee View
50% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 27.5% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Price structure making lower highs and lower lows — Technical
- Price structure (HH_HL) contradicts the downtrend -- mixed signals — Technical
- Bollinger bandwidth of 27.5% signals elevated volatility — Risk